Vericel Corporation (VCEL) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Vericel Corporation (VCEL) Healthcare & Pipeline Overview

Vericel Corporation focuses on cell therapy products for sports medicine and burn care, marketing MACI for knee cartilage repair and Epicel for burn treatment. With a strong gross margin of 74.8% and a P/E ratio of 78.90, Vericel operates in a specialized segment of the biotechnology industry.

What Is the Investment Thesis for VCEL?

The company's key value drivers include the continued adoption of MACI for knee cartilage repair and Epicel for burn treatment. With a gross margin of 74.8%, Vericel demonstrates strong profitability in its niche markets. Growth catalysts include the potential approval and commercialization of NexoBrid for eschar removal, which could significantly expand the company's addressable market. However, investors should be aware of potential risks, including competition from alternative treatments and the inherent challenges in developing and commercializing cell therapies. The company's P/E ratio of 78.90 suggests a premium valuation, reflecting investor expectations for future growth. Monitoring the company's ability to maintain its market share and successfully launch new products will be crucial for assessing its long-term investment potential.

Based on FMP financials and quantitative analysis

VCEL Key Highlights

Market Cap of $1.92B reflects investor confidence in Vericel's growth potential in the cell therapy market.

• P/E Ratio of 78.90 indicates a premium valuation, suggesting high expectations for future earnings growth.
• Gross Margin of 74.8% demonstrates strong profitability and efficient cost management in the production of cell therapies.
• Profit Margin of 7.3% shows the company's ability to convert revenue into profit after accounting for all expenses.
• Beta of 1.21 suggests that the stock is more volatile than the market, indicating higher potential risk and reward.

Who Are VCEL's Competitors?

VCEL is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are VCEL's Key Strengths?

Proprietary cell therapy technologies.

• Established market position in sports medicine and burn care.
• Regulatory exclusivity for key products.
• Specialized manufacturing capabilities.

What Are VCEL's Weaknesses?

Reliance on a limited number of products.

• High cost of cell therapy manufacturing.
• Complex regulatory requirements.
• Limited geographic reach.

What Could Drive VCEL Stock Higher?

VCEL catalyst: Potential FDA approval of NexoBrid for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.

• Continued expansion of MACI into new orthopedic practices and hospitals.
• Increasing awareness and adoption of Epicel for burn treatment through educational programs and clinical data.

What Are the Key Risks for VCEL?

Rich valuation — a P/E of 78.90 runs well above the Healthcare sector’s ~21.50x, leaving little room for a miss.

• Competition from alternative cartilage repair techniques and burn treatment products.
• Unfavorable changes in healthcare regulations and reimbursement policies.
• Challenges in manufacturing and scaling up cell therapy production.
• Product liability claims related to cell therapy products.

What Are the Growth Opportunities for VCEL?

• Expansion of MACI into new patient segments: Vericel has the opportunity to expand the use of MACI beyond its current indications by targeting patients with earlier-stage cartilage damage or those who have failed other treatments. The market for cartilage repair is estimated to be worth several billion dollars annually, and Vericel can capture a larger share by demonstrating the long-term efficacy and cost-effectiveness of MACI. This expansion could be realized within the next 3-5 years through additional clinical trials and marketing efforts.
• Commercialization of NexoBrid for eschar removal: The potential approval and commercialization of NexoBrid represents a significant growth opportunity for Vericel. NexoBrid offers a non-surgical alternative for eschar removal in burn patients, potentially reducing the need for invasive procedures and improving patient outcomes. The market for burn care products is estimated to be worth over $1 billion annually, and NexoBrid could capture a significant share of this market. Regulatory approval is anticipated within the next 1-2 years, followed by commercial launch.
• Geographic expansion into international markets: Vericel currently focuses on the US market, but there is significant potential to expand into international markets, particularly Europe and Asia. These markets have a large patient population with unmet needs in sports medicine and burn care. Vericel can partner with local distributors or establish its own sales force to penetrate these markets. This expansion could be realized within the next 3-5 years, driving significant revenue growth.
• Development of new cell therapy products: Vericel can leverage its expertise in cell therapy to develop new products for other indications, such as osteoarthritis, wound healing, and regenerative medicine. The company can invest in research and development to identify promising new cell therapy candidates and conduct clinical trials to demonstrate their safety and efficacy. This long-term growth strategy could diversify Vericel's product portfolio and reduce its reliance on MACI and Epicel.
• Strategic acquisitions and partnerships: Vericel can pursue strategic acquisitions and partnerships to expand its product portfolio, access new technologies, and strengthen its market position. The company can acquire smaller companies with complementary products or technologies, or partner with larger companies to co-develop and commercialize new products. This inorganic growth strategy can accelerate Vericel's expansion into new markets and therapeutic areas.

What Are VCEL's Competitive Advantages?

• Proprietary cell therapy technologies: Vericel's autologous cell therapy platforms, including MACI and Epicel, are protected by patents and trade secrets, providing a competitive advantage.
• Established market position: Vericel has a strong market presence in the sports medicine and burn care markets, with established relationships with key opinion leaders and hospitals.
• Regulatory exclusivity: MACI and Epicel have received regulatory approvals and orphan drug designations, providing market exclusivity and protection from competition.
• Manufacturing expertise: Vericel has specialized manufacturing capabilities for cell therapy products, which are difficult to replicate.

What Does VCEL Do?

Vericel Corporation, founded in 1989 and headquartered in Cambridge, Massachusetts, is a commercial-stage biopharmaceutical company focused on developing and marketing advanced cell therapies. Originally known as Aastrom Biosciences, Inc., the company has evolved to specialize in autologous cell therapy products for the sports medicine and severe burn care markets. Vericel's flagship product, MACI (autologous cultured chondrocytes on porcine collagen membrane), is designed for the repair of symptomatic, single, or multiple full-thickness cartilage defects of the knee. This innovative product utilizes a patient's own cells to regenerate cartilage, offering a personalized approach to treatment. Another key product is Epicel (cultured epidermal autografts), a permanent skin replacement humanitarian use device used in the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Epicel provides a life-saving solution for patients with extensive burns, reducing mortality and improving recovery. Vericel is also developing NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. This product aims to provide a non-surgical option for burn wound management, potentially reducing the need for invasive procedures. The company's commitment to innovation and patient-specific therapies positions it as a key player in the regenerative medicine space.

What Products and Services Does VCEL Offer?

• Develops and markets autologous cell therapy products.
• Offers MACI for the repair of knee cartilage defects.
• Provides Epicel for the treatment of deep-dermal or full-thickness burns.
• Focuses on regenerative medicine solutions.
• Conducts research and development in cell therapy.
• Manufactures and distributes cellular therapies in the United States.
• Aims to improve patient outcomes through innovative cell-based treatments.

How Does VCEL Make Money?

• Develops and manufactures autologous cell therapy products.
• Markets and sells MACI for knee cartilage repair to orthopedic surgeons and hospitals.
• Markets and sells Epicel for burn treatment to burn centers and hospitals.
• Generates revenue through product sales and distribution agreements.

What Industry Does VCEL Operate In?

Vericel Corporation operates within the biotechnology industry, specifically focusing on cell therapies for sports medicine and burn care. The regenerative medicine market is experiencing growth, driven by advancements in cell biology and increasing demand for personalized treatments. The competitive landscape includes companies developing alternative cartilage repair techniques and burn treatment products. Vericel's focus on autologous cell therapies provides a unique value proposition, leveraging a patient's own cells for treatment. The company's success depends on its ability to maintain a competitive edge through innovation, clinical data, and market access.

Who Are VCEL's Key Customers?

• Orthopedic surgeons who perform knee cartilage repair procedures.
• Burn centers and hospitals that treat patients with severe burns.
• Patients with symptomatic knee cartilage defects.
• Patients with deep-dermal or full-thickness burns.

Over the past six months, Vericel Corporation insiders filed 76 SEC Form 4 transactions — 19 sales and 57 purchases. On net that is roughly 219K shares acquired (about $42K) — insiders putting money in tends to read as conviction.

Vericel Corporation has beaten Wall Street's EPS estimate in 6 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 107.5% above estimates on average.

Vericel Corporation's Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 9.24 places it in the safe zone, indicating low near-term bankruptcy risk.

Return on equity for Vericel Corporation stands at 6.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 4.8%, showing how much profit it generates from its asset base. VCEL trades at a trailing price-to-earnings ratio of 78.90, above the Healthcare sector average of ~21.50x. Its free cash flow yield is 2.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 5.04 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 1.2%, the inverse of the P/E and a quick read on earnings relative to price.

Vericel Corporation (VCEL) Valuation Context

Valued at $1.92B, VCEL is classified as a small-cap stock. Analyst price targets span from $54.00 to $70.00, with a consensus of $61.33. At the current price of $37.50, that implies approximately 64% upside potential. Relative to its peer group, VCEL's quantitative score of 91/100 is roughly in line with the peer average of 84/100.

VCEL Revenue & Earnings Trend

In Q2 FY2026, VCEL generated $77.5M in top-line revenue, marking a sequential increase of 13.2%. The company recorded net income of $2.2M, with diluted EPS of $0.04. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare. Across the four most recent quarters, VCEL averaged $0.12 in diluted EPS.

Company Profile

Vericel Corporation operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Burlington, US. The company is led by CEO Dominick C. Colangelo. VCEL has traded publicly since 1997.

VCEL Financials

VCEL Latest News

VCEL Analyst Consensus

VCEL MoonshotScore

VCEL Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources